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usually do not exceed 60%.
OBJECTIVES This study sought to compare arrhythmia-free survival between pulmonary vein isolation (PVI) and a
stepwise approach (full defrag) consisting of PVI, ablation of complex fractionated electrograms, and additional linear
ablation lines in the setting of atrial tachycardias (AT) in patients with persistent AF after PVI.
METHODS From November 2010 to February 2013, 205 patients (151 men; 61.7  10.2 years of age) underwent de novo
ablation for persistent AF. Subsequently, patients were prospectively randomized to either PVI alone (n ¼ 78) or full
defrag (n ¼ 75), with 52 patients not randomized due to AF termination with the original PVI. The primary endpoint was
recurrence of any AT after a blanking period of 3 months.
RESULTS During the entire study, 241 ablations were performed (mean: 1.59 in the PVI-alone group, 1.55 in the
full-defrag group). With the stepwise approach, termination of AF occurred in 45 (60%) patients. However, arrhythmia-
free survival did not differ whether patients underwent single or multiple procedures (p ¼ 0.468). Procedure duration,
ﬂuoroscopy time, and radiofrequency duration were signiﬁcantly longer in the full-defrag group (all p < 0.001).
CONCLUSIONS A stepwise approach aimed at AF termination does not seem to provide additional beneﬁt over PVI
alone in patients with persistent AF, but it is associated with signiﬁcantly longer procedural and ﬂuoroscopic duration as
well as radiofrequency application time. (The Randomized Catheter Ablation of Persist End Atrial Fibrillation Study
[CHASE-AF]; NCT01580124) (J Am Coll Cardiol 2015;66:2743–52)
© 2015 by the American College of Cardiology Foundation.A well-established therapy for paroxysmalatrial ﬁbrillation (PAF), pulmonary veinisolation (PVI), is associated with encour-
aging long-term results and has proven to be superior
to antiarrhythmic therapy for long-term rhythm sta-
bility (1–3). However, PVI alone appears to be insuf-
ﬁcient for treating persistent AF (persAF), withm the *Department of Electrophysiology, University Heart Center Ha
rmany; yDepartment of Electrophysiology, University Heart Center Colog
epartment of Electrophysiology, Clinic Hirslanden-Heart Center, Zurich
elspital, Bern University Hospital and University of Bern, Bern, Switzerlan
dical GmbH, Eschborn, Germany. St. Jude Medical is not responsible for a
nter Hamburg and Dr. Willems were completely in charge of the design a
nt, analysis, and interpretation of the data, as well as preparation of the m
reau for St. Jude Medical, Biosense Webster, Boston Scientiﬁc, Boehrin
earch grants from St. Jude Medical, Biosense Webster, Boehringer Ingelhe
t they have no relationships relevant to the contents of this paper to dis
nuscript received January 29, 2015; revised manuscript received Septembdisappointing long-term results (4–10). Therefore,
additional ablation strategies targeting the modiﬁca-
tion and elimination of the AF-sustaining atrial sub-
strate have been developed, including ablation of
complex fractionated atrial electrograms (CFAEs)
(6,11) in both atria and the coronary sinus (CS),
isolation of the left atrial appendage (LAA), andmburg, University Hospital Eppendorf, Hamburg,
ne, University Hospital Cologne, Cologne, Germany;
, Switzerland; and the xDepartment of Cardiology
d. The study was funded with 154,000 V by St. Jude
ny speciﬁc role within the trial. The University Heart
nd implementation of the trial, collection, manage-
anuscript. Dr. Willems is a member of the speakers
ger Ingelheim, and Bayer Vital; and has received
im, and Bayer Vital. All other authors have reported
close.
er 7, 2015, accepted September 24, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
AAD = antiarrhythmic drugs
AF = atrial ﬁbrillation
AT = atrial tachycardia
CFAE = complex fractionated
atrial electrograms
CS = coronary sinus
DC = direct current
ECG = electrocardiogram
LA = left atrium
LAA = left atrial appendage
PAF = paroxysmal atrial
ﬁbrillation
persAF = persistent atrial
ﬁbrillation
PVI = pulmonary vein isolation
RA = right atrium
Vogler et al. J A C C V O L . 6 6 , N O . 2 4 , 2 0 1 5
The CHASE-AF Study D E C E M B E R 2 2 , 2 0 1 5 : 2 7 4 3 – 5 2
2744deployment of linear lesions in the left
atrium (LA) (12–14). Despite these strategies,
arrhythmia recurrence is common in patients
with persAF, often leading to repeat ablation.
The CHASE-AF (Catheter Ablation of Per-
sistend Atrial Fibrillation) study was designed
to compare a strategy for AF termination
using a stepwise approach consisting of PVI
followed by biatrial ablation of CFAEs and
linear ablation lines in the case of atrial
tachycardias (AT) versus PVI alone in patients
with persAF in whom AF does not terminate
with a single PVI.
METHODS
We enrolled 205 patients (61.7  10.2 years)
with persAF at the University Heart Center
Hamburg, Hamburg, Germany. PersAF was
deﬁned as an episode lasting >7 days (docu-mented on an electrocardiogram [ECG]) or a history of
electrical cardioversion (regardless of the time in AF
before cardioversion, but with a history consistent
with persAF). Exclusion criteria were age <18 or >80
years, previous operative or interventional treatment
of AF, PAF, pregnancy, contraindication for oral
anticoagulation or heparin administration, transient
factors causing AF, drug and/or alcohol abuse, and
severe underlying heart disease with LA enlargement
of >60 mm. The study was approved by the local
institutional review board and ethics committee, and
funded by St. Jude Medical, Inc. (St. Paul, Minnesota).
All patients provided written informed consent.SEE PAGE 2753STUDY DESIGN. Following PVI, patients were ran-
domized 1:1 to PVI alone or a stepwise ablation
approach (full-defrag group). To rule out patients
with PV-dependent AF, patients whose AF was
terminated with PVI were excluded before randomi-
zation. The index procedure in the PVI-alone group
consisted of a circumferential PVI, including optional
right atrial (RA) isthmus ablation followed by direct
current (DC) cardioversion. Entrance block evaluated
by a circumferential mapping catheter during sinus
rhythm at the procedure’s end deﬁned the endpoint.
Patients in the full-defrag group received additional
CFAE ablation in both atria, the CS, and linear abla-
tion in the setting of AT as previously described
(Figure 1) (15–18). We checked all linear ablation lines
for bidirectional block after attaining sinus rhythm. If
AF termination was not achieved, the procedure
was stopped after a maximum of 6 h or if a maximum
of 5 l of ﬂuid had been administered to the patient(17). DC cardioversion was performed. Intraproce-
dural antiarrhythmic drugs (AADs) were used at the
operator’s discretion. Previous AAD treatment was
continued for a maximum of 6 months after the index
procedure, but de novo AADs were not allowed.
The primary endpoint was recurrence of any
documented atrial arrhythmia that lasted >30 s be-
tween 3 and 12 months after the ﬁrst procedure
(including a blanking period of 3 months). Secondary
outcomes included procedure and ﬂuoroscopy dura-
tion, radiofrequency (RF) application time, number of
procedures, incidence of peri-procedural complica-
tions, antiarrhythmic therapy, and achieving the pri-
mary endpoint after a single ablation.
Transesophageal echocardiography was performed
in all patients to rule out LA thrombus. Oral anti-
coagulation was stopped at least 3 days before ablation
and replaced by low-molecular-weight heparin. The
electrophysiological study was performed under deep
sedation. The catheter setting consisted of a steerable
6-F 10-polar CS catheter, a circumferential 7-F 10-polar
mapping catheter for PV mapping, one 4-polar cath-
eter for mapping of the RA, and a 7-F externally irri-
gated catheter for mapping and ablation. All catheters
were introduced via femoral access. A single trans-
septal puncture was performed for the mapping and
ablation catheters placed into the LA. Intravenous
heparin was administered after the trans-septal
puncture, targeting an activated clotting time be-
tween 250 and 300 s (ACT controls every 30 min).
Trans-septal sheaths were continuously ﬂushed with
heparinized saline. In all patients, the 3-dimensional
mapping system (EnSite NavX, St. Jude Medical) pro-
vided electroanatomical reconstruction of the LA. RF
current was applied with a maximum power of 30 W,
using an irrigation rate of 10 to 30 ml/min for the PVs,
35 W, and an irrigation rate between 30 and 60 ml/min
in the LA, and up to 30 W in the RA. RF power was
limited to 25 W for ablation within the CS, with the
irrigation rate manually adjusted to keep the tip tem-
perature below 42C.
We saw all patients every 3 months in our outpa-
tient clinic. Follow-up visits included a detailed his-
tory, ECG, 24-h Holter recording at least every 3
months, and 72-h Holter monitoring at the 12-month
follow-up visit. In the event of arrhythmia recur-
rence, patients underwent a repeat procedure be-
tween 3 and 6 months after the ﬁrst procedure. To
avoid crossover between the 2 groups, the approach
for the repeat procedure was the same as the index
procedure. In case of a complete entrance block or
insigniﬁcant slow passive conduction of 1 PV (cycle
length in the PV is longer than in the RA, LAA, and
CS), patients initially randomized to the PVI-alone
FIGURE 1 Stepwise Ablation Approach
Atrial fibrillation
Step 1
Pulmonary vein isolation
(n = 75)
Step 2
LA Defragmentation
(n = 75)
CS Defragmentation
(n = 61)
RA Defragmentation
(n = 68)
Atrial tachycardia
(n = 27)
Step 3
Mapping and ablation of AT
n = 30
n = 11
n = 11
n = 1
n = 6
n = 16
Sinus rhythm
Electrical cardioversion
Term
ination
The subsequent ablation steps used with the stepwise approach. AT ¼ atrial tachycardia;
CS ¼ coronary sinus; LA ¼ left atrium; RA ¼ right atrium.
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other group.
STATISTICAL ANALYSIS. Assuming an absolute risk
reduction of 30% for the stepwise approach compared
with PVI in the primary outcome, the estimated
sample size per group was 65 patients to provide 95%
power with an alpha error of 5%. To account for a
potential dropout rate of 10%, 160 patients were
planned for inclusion. Baseline patient characteris-
tics, procedure-related data, and arrhythmia-free
survival were compared using the Mann-Whitney
U test for continuous variables and the chi-square
test or Fisher exact test (if the expected frequencies
were low) for categorical variables. Continuous vari-
ables are expressed as mean  SD for normal distribu-
tion or asmedian and interquartile ranges in the case of
other distribution. Categorical variables are summa-
rized as counts and percentages. Event-free survival
was displayed with Kaplan-Meier curves and com-
pared by the log-rank test. Throughout all calculations,
a 2-tailed p value of 0.05 was considered statistically
signiﬁcant. Alpha adjustment for multiple testing was
not applied; therefore, results are of an exploratory
and descriptive character. An independent statistician
performed all analyses using SPSS version 22 (IBM
Corporation, Armonk, New York).
RESULTS
From November 2010 to February 2013, 205 patients
with persAF (mean age: 61.7  10.2 years; 151 men)
were enrolled and assigned to PVI alone (n ¼ 78), full
defrag (n ¼ 75), or not randomized (n ¼ 52) due to
termination of AF with PVI (Figure 2). There were no
differences in baseline characteristics except for the
longest episode of continuous AF, which was longer
in the PVI-alone group (Table 1). An equal number of
patients in the PVI and defrag groups were on anti-
arrhythmic therapy before ablation (Table 1).
A total of 142 patients were eligible for rhythm
outcome analysis; 11 patients (7 in the PVI-alone group,
4 in the full defrag group) were lost to or had incom-
plete follow-up. In the PVI-alone group, 10 patients
were treated with a stepwise approach during the
repeat procedure (second or third ablation) due to
isolated PVs and excluded from rhythm outcome
analysis to avoid bias by crossover. No patient died
during follow-up.
All patients were in spontaneous AF at the begin-
ning of the procedure. Baseline AF cycle length did not
differ (Table 2). In the PVI-alone group, sinus rhythm
was achieved by DC cardioversion. In the full-defrag
group, mean AF cycle length progressively increased
during CFAE ablation (Figure 3). AF termination wasachieved in 45 (60%) patients: 18 patients converted to
sinus rhythm during ablation of CFAE in the LA, RA,
or CS. In 27 patients, AF was converted to AT; 11 of
these patients required cardioversion because AT
could not be terminated by ablation. Failure to termi-
nate was mainly due to unstable AT combined with
prolonged procedure duration, high volume load, and
barely mappable electrograms after extensive abla-
tion. AF was not terminated in the remaining 30 pa-
tients. Procedure duration, ﬂuoroscopy time, and RF
duration were longer in the full-defrag group, and
patients had a higher ﬂuid intake (Table 2).
In the full-defrag group, 22 patients underwent
linear ablation: mitral isthmus line in 6 patients; mitral
isthmus line plus ablation at the cavotricuspid isthmus
in 2 patients; mitral isthmus line plus LA roof line in 2
patients; anterior line in 1 patient; anterior line plus
linear ablation at the cavotricuspid isthmus in 1 pa-
tient; LA roof line and linear ablation at the cavo-
tricuspid isthmus in 1 patient; and ablation at the
cavotricuspid isthmus in 8 patients. Bidirectional
block was achieved in 20 of these 22 patients. The
remaining 2 patients showed an incomplete block at
the mitral isthmus line.
FIGURE 2 Study Flowchart
205 patients with persistent AF
assessed for eligibility received
PVI
52 patients excluded due
to termination of AF
153 patients randomized
78 patients assigned to PVI and
received PVI–alone plus DC
75 patients assigned to and
received full defragmentation 1. Index procedure
18 patients received
re–isolation of PVs
17 patients received a second
full defragmentation 2. Procedure
8 patients received a second
re–isolation of PVs
12 patients received a third
full defragmentation 3. Procedure
7 patients lost to follow–up
10 patients excluded from
analysis due to cross–over
during 2. or 3. procedure
4 patients lost to follow–up
or with incomplete follow–up
Patients with persistent atrial ﬁbrillation (AF) that did not terminate after initial pulmonary vein isolation (PVI) were randomized to subsequent
PVI or full defragmentation (full defrag). DC ¼ direct current cardioversion; PV ¼ pulmonary vein.
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2746RHYTHM OUTCOME. During the entire study, 241 ab-
lations were performed in 153 patients (mean: 1.59 in
the PVI-alone group, 1.55 in the full-defrag group).
Single ablation was performed in 88 patients, 2 abla-
tions in 41 patients, and 3 ablations in 24 patients.
(As discussed earlier, 10 patients in the PVI group
required the stepwise approach.) After single (Figure 4)
and multiple procedures (Central Illustration),
arrhythmia-free survival (on drug therapy) did not
differ between the 2 groups: by per-protocol analysis,
sinus rhythm was maintained in 39 of 61 (63.9%) pa-
tients in the PVI-alone group versus 41 of 71 (57.7%)
patients in the full-defrag group (p ¼ 0.468). By
intention-to-treat analysis, arrhythmia-free survival
was also similar (61.4% in the PVI group vs. 58.3% in the
full-defrag group; p ¼ 0.707). The drug-free overall
1-year multiple procedure success rate was 51.4% in
the PVI-alone group compared with 50.0% in the
full-defrag group (p ¼ 0.865). PAF recurred in 4 (6.6%)patients in the PVI-alone group and in 8 (11.3%) pa-
tients in the full-defrag group; for persAF, the corre-
sponding numbers were 18 (29.5%) and 19 (26.8%)
patients (p ¼ 0.635), respectively. No difference was
seen in the rate of ATs: 5 (8.2%) patients in the
PVI-alone group, and 6 (8.5%) in the full-defrag group
(p > 0.999). Termination of AF during the ﬁrst proce-
dure was not associated with better arrhythmia-free
survival; 13 patients (21.3%) in the PVI group and 20
patients (28.2%) in the full-defrag group were still or
once again on antiarrhythmic medication at the last
follow-up visit (p ¼ 0.364).
A subanalysis that evaluated the arrhythmia-free
survival after 12 months according to the number of
ablations within the follow-up period was consistent
with the results of the overall study population
(Table 3). There was no difference between the 2
treatment groups, and there was no trend toward a
difference for either group. With few patients who
TABLE 1 Baseline Characteristics
PVI
(n ¼ 78)
Full Defragmentation
(n ¼ 75) p Value
Patient demographics
Age, yrs 63.0  9.6 61.1  10.9 0.43
Male 56 (71.8) 60 (80.0) 0.24
Body mass index, kg/m2 27.2  4.7 27.5  3.2 0.78
Baseline dates concerning AF
History of AF, months 52.1  47.7 64.4  61.2 0.56
Longest episode of AF, days 324.0  435.8
184.3 (121.7–365.2)
167.0  130.9
152.2 (64.93–235.9)
0.03
CHA2DS2-VASc score 2.1  1.3 1.7  1.3 0.10
Medical history
Coronary artery disease 21 (26.9) 12 (16.0) 0.10
Valvular heart disease 5 (6.4) 2 (2.7) 0.44
Arterial hypertension 65 (83.3) 57 (76.0) 0.26
Dyslipidemia 39 (50.0) 26 (34.7) 0.06
Baseline echocardiographic measurements
LVEF, % 60.0  7.1 59.8  7.1 0.99
LA diameter, mm 44.5  6.6 43.7  5.2 0.30
Antiarrhythmic therapy before ablation 35 (46.1) 35 (46.7) 0.94
Amiodarone 20 (26.3) 17 (22.7)
Flecainide/propafenone 9 (11.6)/1 (1.0) 9 (12)/0 (0.0)
Dronedarone 4 (5.3) 8 (10.7)
Values are mean  SD, n (%), or median (interquartile range).
AF ¼ atrial ﬁbrillation; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes
mellitus, prior stroke or TIA or thromboembolism, vascular disease, age 65-74 years, sex; LA ¼ left atrium;
LVEF ¼ left ventricular ejection fraction; PVI ¼ pulmonary vein isolation.
TABLE 2 Procedural Data
Variable PVI
Full
Defragmentation p Value
Baseline AFCL, ms
LAA 171.9  28.8 168.4  34.8 0.73
RAA 172.7  31.3 173.0  37.0 0.62
CS 180.9  123.0 166.7  32.8 0.38
LSPV 177.6  32.4 175.0  36.7 0.87
LIPV 176.6  30.9 175.9  28.8 0.93
RSPV 181.5  34.3 188.4  33.3 0.16
RIPV 182.3  29.8 183.0  26.9 0.65
Procedure duration, min 124.9  36.5 220.6  58.2 <0.001
Radiofrequency
application time, min
45.0  22.5 99.9  36.2 <0.001
Fluoroscopy time, min 26.9  12.3 52.7  18.3 <0.001
Fluid intake, ml 1,356.9  600.5 2,821.1  942.3 <0.001
Values are mean  SD.
AFCL ¼ atrial ﬁbrillation cycle length; CS ¼ coronary sinus; LAA ¼ left atrial
appendage; LIPV ¼ left inferior pulmonary vein; LSPV ¼ left superior pulmonary
vein; PVI ¼ pulmonary vein isolation; RAA ¼ right atrial appendage; RIPV ¼ right
inferior pulmonary vein; RSPV ¼ right superior pulmonary vein.
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limited. Arrhythmia-free survival (on drugs) in pa-
tients who required single ablation was higher than
expected in patients with persAF, but was not supe-
rior with the stepwise approach (75% vs. 73.8%;
p ¼ 0.904) (Table 3). Baseline characteristics were
similar in both treatment groups.
Amiodarone was the AAD most commonly used in
both groups, followed by ﬂecainide. Twenty-nine
(19.9%) patients were started on AADs within the
ﬁrst 3 months due to symptomatic AF. After 12-month
follow-up, 104 (73.2%) patients were off AADs,
whereas 38 (26.8%) patients were still or once again
on antiarrhythmic medication.
ADVERSE EVENTS. Major procedure-related compli-
cations (patient-related, pericarditis excluded) did not
differ signiﬁcantly between the 2 groups (PVI 5.1% vs.
full defrag 13.3%; p ¼ 0.078). In the full-defrag group,
1 patient had a procedure-related stroke with minimal
residual neurological impairment and 1 patient devel-
oped cardiac tamponade. The incidence of pericardial
effusion with symptoms of pericarditis was higher in
the full-defrag group (5.3% vs. 23.3%; p ¼ 0.002; odds
ratio: 5.46, 95% conﬁdence interval: 1.74 to 17.15). No
difference was seen in the rate of vascular access
complications between the 2 groups. The relatively
high overall incidence of procedure-related complica-
tions was mainly due to vascular complications.
DISCUSSION
Our study showed that: 1) sole PVI was comparable to
a stepwise approach aimed at terminating persAF
after a 12-month follow-up (Central Illustration);
2) arrhythmia-free survival was higher than antici-
pated in both treatment groups for those patients
who required single ablation; and 3) a stepwise
approach was associated with a longer procedure
duration, ﬂuoroscopy time, and RF duration, but did
not result in a higher rate of major complications.
This is one of the ﬁrst studies to directly compare
PVI and a stepwise approach in patients with persAF
in whom AF did not terminate after PVI. Based on
previous studies of patients with persAF (10,16,19–21)
and our own experiences with such patients (15),
which showed improved success rates with a step-
wise approach, we hypothesized that the stepwise
approach would produce a beneﬁt.
Why did the stepwise approach fail in this regard?
Most patients in previous studies had chronic persAF.
The deﬁnition of chronic AF, however, has not
been uniform, ranging from a minimum of 1 month
(10,16) up to >12 months (the ofﬁcial deﬁnition for
long-standing persAF by the European Heart RhythmAssociation). This entity of AF seems to be associated
with more advanced disease. Therefore, PVI alone
may be insufﬁcient to restore sinus rhythm in these
patients. However, in our study, the longest episode
of continuous AF had been <12 months in most pa-
tients, and continuous AF episodes ranged widely,
FIGURE 3 Mean AFCL Progression
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2748from 1 day to >12 months. This suggests a different
population of patients with a less advanced type of
AF compared with previous studies. A subset of pa-
tients might have had AF of paroxysmal character.FIGURE 4 Rhythm Outcome After Single Ablation
1.0
0.8
0.6
0.4
0.2
0.0
Fr
ee
do
m
 o
f R
ec
ur
re
nc
e 
fr
om
 A
ny
 A
T/
AF
 [x
10
0%
]
0 200
Time to
Log rank test: p = 0.105
Numbers at risk
PVI
Full defrag
74
74
49
58
33
44
27
35
Kaplan-Meier event-free survival curve demonstrates arrhythmia-free suAdditional CFAE ablation is not beneﬁcial for sinus
rhythm maintenance in these patients (20,22–25);
consequently, PVI might have been comparable to the
stepwise approach in our study. AF termination rate
in the full-defrag group was lower than in the
Bordeaux group studies (16,26). However, compared
with other studies (27–29), including STAR AF II (the
Substrate and Trigger Ablation for Reduction of Atrial
Fibrillation Trial Part II) (30) and our own experience,
a termination rate of 60% is reasonable if patients
with successful AF termination following PVI are
excluded and if linear ablation lines are only per-
formed in cases of ATs. Assuming that AF termination
during the procedure is 1 of the strongest predictors
of procedure outcome, as shown in some previous
studies (15,31), arrhythmia-free survival should have
been superior in patients with AF termination. How-
ever, the results of the STAR AF II trial and our study
do not support that assumption (1,28,32). There is
conﬂicting evidence as to whether AF termination
during ablation inﬂuences long-term outcome.
Therefore, the outcome value of AF termination
remains controversial in a “real-world scenario.”
PATIENT CHARACTERISTICS. Long-term efﬁcacy of
PVI as the ﬁrst-line ablative strategy in persAF is
questionable. However, Tilz et al. (8,9) reported
that 43.2% of patients were arrhythmia free after a400 600
 Recurrence [Days]
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CENTRAL ILLUSTRATION Catheter Ablation of Persistent Atrial Fibrillation: Pulmonary Vein Isolation
Versus Defragmentation
Vogler, J. et al. J Am Coll Cardiol. 2015; 66(24):2743–52.
In comparing pulmonary vein isolation (PVI) to defragmentation (full defrag), recurrence per treatment group after a follow-up of 3, 6, 9, and
12 months is shown for (top) atrial ﬁbrillation (AF), including both paroxysmal and persistent AF patients, and (bottom) any atrial arrhythmia
(10 crossover patients excluded). The stepwise approach (full defrag) did not appear to provide additional beneﬁt over PVI alone in these patients.
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TABLE 3 12-Month Rhythm Outcome According to Number of Ablations
No. of Ablations Rhythm Outcome PVI
Full
Defragmentation p Value
1 (PVI: n ¼ 36; full defrag: n ¼ 42) Survival free of atrial arrhythmia 27 (75.0) 31 (73.8) 0.90
Recurrence of PAF/persAF 3 (8.3)/6 (16.7) 3 (7.1)/7 (16.7) 0.98
2 (PVI: n ¼ 18; full defrag: n ¼ 17) Survival free of atrial arrhythmia 10 (55.6) 5 (29.4) 0.12
Recurrence of PAF/persAF 1 (5.6)/7 (38.9) 3 (17.6)/8 (47.1) 0.36
3 (PVI: n ¼ 7; full defrag: n ¼ 12) Survival free of atrial arrhythmia 2 (28.6) 5 (41.7) 0.57
Recurrence of PAF/persAF 0 (0)/5 (71.4) 2 (16.7)/4 (33.3) 0.22
Values are n (%).
full defrag ¼ full defragmentation; PAF ¼ paroxysmal atrial ﬁbrillation; persAF ¼ persistent atrial ﬁbrillation; PVI ¼ pulmonary vein isolation.
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patients were arrhythmia free after 5 years following
PVI as the sole ablative strategy. In contrast to their
study, we excluded patients with AF termination
following PVI. PVI responders in the study by Tilz
et al. (9) had a smaller LA diameter and a shorter total
AF duration compared with PVI nonresponders. The
average LA diameter in both of our treatment groups
was smaller, and AF duration was substantially
shorter than that in their study, as well as in the
Bordeaux studies, which indicated a less advanced AF
phenotype. Therefore, a considerable amount of our
patients may have been PVI responders, resulting in
PVI noninferiority.
Finally, permanent electrical isolation of all PVs by
creation of durable lesions is critical because recur-
rence of atrial arrhythmias after ablation of persAF is
also related to reconnected PVs. Newer techniques
like contact force, recognition of dormant conduction
by adenosine, or PVI guided by loss of pace capture
on the ablation line (33), as well as the new generation
of cyroballoons, can help reduce the problem of PV
reconduction.
INTERPRETATION OF CFAES. Since the promising
study of Nademanee (11), the addition of CFAE ablation
has been suggested to improve long-term freedom
from AF. However, different trials results have been
highly variable, and extensive ablation may have un-
intentionally created new substrates responsible for
additional atrial arrhythmias. Patients in our study did
not seem to beneﬁt from extensive biatrial defrag-
mentation. This ﬁnding is consistent with increasing
evidence that CFAEs might not represent critical sites
for AF perpetuation, but might correspond to areas of
normal atrial voltage and conduction (34–36). More
recent evidence suggests that stable rotors and focal
sources may sustain human AF (36). Furthermore, the
exact mechanism by which CFAE ablation could
improve arrhythmia-free outcome remains unclear,
the deﬁnition of CFAEs varies in different centers, and
CFAE stability has been questioned (37).Like earlier results in catheter ablation of persAF,
our data underline a trend toward being even more
selective in treating patients with persAF. AF termi-
nation during ablation, which has been identiﬁed as
a predictor of success in some previous studies
(15,17,18,31), does not seem to correlate with better
arrhythmia-free survival. The termination rate in our
study (60%) is consistent with those presented in
previous multicenter trials, such as STAR AF II (30).
Nevertheless, the STAR AF II trial, the RASTA study
(Randomized Ablation Strategies for the Treatment of
Persistent Atrial Fibrillation) (27), and a recently
published meta-analysis (29) did not demonstrate a
beneﬁt of CFAE ablation. The results favored lone PVI
at least as an initial approach, and our results un-
derline the presumption that less may be more in
selected patients with persAF. However, the long-
term success rates of lone PVI, even after multiple
procedures, are low (9), indicating additional ablation
is needed in some patients. Whether these ap-
proaches in the future will rely more on a substrate-
based approach or a phased mapped–derived rotor
concept needs to be determined and requires a better
understanding of AF pathophysiology (35,36,38,39).
STUDY LIMITATIONS. Compared with other studies,
our follow-up period may have been too short to
detect differences in arrhythmia outcome between
the 2 treatment groups. In addition, in patients who
were on amiodarone for up to 6 months, a follow-up
of 12 months might have been too short to deter-
mine the drug-free success rate. Patients in the
CHASE-AF study received the recommended mini-
mum assessment of AF documentation (1) during
follow-up. Due to the nature of AF, assessment by an
implantable loop recorder is superior to Holter
ECGs; therefore, the overall success rate may have
been overestimated. Some patients with AF recur-
rence did not undergo re-ablation because of symp-
tom improvement or complete symptom relief, which
might have decreased our success rate. The deﬁnition
of persAF as a history of at least 1 DC cardioversion,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: A substrate-
based, extensive ablation approach (stepwise) to patients with
persistent AF does not improve arrhythmia-free survival
compared with PVI alone over 12 months of post-procedural
follow-up.
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: PVI should be the initial strategy in patients with
persistent AF undergoing catheter ablation, because more
extensive ablation is associated with longer procedure duration,
ﬂuoroscopy, and radiofrequency exposure without better rhythm
control outcomes.
TRANSLATIONAL OUTLOOK: Further studies are needed
to deﬁne the safety and efﬁcacy of ablation of AF rotors and
other focal sources to improve outcomes in patients with
persistent AF.
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2751regardless of the time in AF before cardioversion, is
critical; patients with short-lasting (<48 h) parox-
ysmal AF might have been included in our study.
However, we think we addressed that issue by
excluding patients with PV-dependent AF before
randomization.
Suppressing potential triggers due to previous
antiarrhythmic therapy can reduce recurrence of
atrial arrhythmias (40). Continuing amiodarone right
up to the ablation and up to 6 months afterwards
may have improved our acute AF termination rate. It
also may have affected our recurrence rates. Never-
theless, our approach of ongoing amiodarone treat-
ment, and thus our results, are comparable to those
of other studies (e.g., the STAR AF II trial [30] and a
study by Scherr et al. [26]). Our ﬂuoroscopy times
are in line with earlier studies, but were longer than
expected when using new image integration mod-
ules and pressure sensor catheters. Without these
newer techniques, and due to the problem of map
stability in impedance-based, 3-dimensional map-
ping, operators used ﬂuoroscopy more intensively,
especially at certain catheter positions at the roof or
the LAA.
CONCLUSIONS
A stepwise approach, aimed at AF termination, did
not seem to provide additional beneﬁt over PVI alone
in patients with persAF. The risk of major complica-
tions was not increased, but patients who underwent
substrate modiﬁcation using the stepwise approachwere exposed to signiﬁcantly longer procedure time
and ﬂuoroscopy duration, as well as increased RF
application time.
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